|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of flow cytometry showed that CDCA2 promoted cell cycle progression via upregulation of CCND1 in CRC cell lines.
|
31196027 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functional characterization reveals that STAT1-CCND1/CDK6 axis is a downstream effector of SETDB1-mediated CRC cell proliferation.
|
31306481 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, biochemical assays illustrated that rs3750050 could impair the inhibitory effect of PTPN12 on Ras/MEK/ERK signaling by impeding SHC dephosphorylation, increase the expression of cyclin D1 and ultimately lead to aberrant cell proliferation, thus contributing to CRC pathogenesis.
|
30731403 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RTHF daily gavage suppressed the number and size of CRC in mice and inhibited Lgr5 and Cyclin D1 expressions in tumor tissue.
|
30323621 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-519d negatively regulated the expression of CCND1 via directly bound to CCND1 3`UTR. si-CCND1 could downregulate the CCND1 expression in colorectal cancer HCT116 and SW480 cells. si-CCND1 increased the sensitivity of colorectal cancer cells to 5-Fu.
|
29771440 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
uc.338 targets p21 and cyclin D1 via PI3K/AKT pathway activation to promote cell proliferation in colorectal cancer.
|
29901203 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, the microarray analysis revealed RAP1A promoted CRC growth partly through phosphatase and tensin homolog (PTEN)/forkhead box O3(FOXO3)/cyclin D1(CCND1) signaling pathway.
|
30064475 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
And miR-203a-3p/β-catenin/Cyclin D1/c-Myc signaling pathway is involved in the CRC.
|
30662799 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Specifically, DJ-1-induced β-catenin nuclear translocation stimulated TCF transcription activity, which promoted BMP4 expression for CRC cell migration and invasion, and elevated CCND1 expression for CRC cell proliferation, respectively.
|
30158634 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1, CDK4 and Ras were revealed to be expressed significantly higher in poorly differentiated CRC compared with moderately differentiated CRC (P<0.05).
|
29552187 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Phenylethynyl-substituted Heterocycles Inhibit Cyclin D1 and Induce the Expression of Cyclin-dependent Kinase Inhibitor p21<sup>Wif1/Cip1</sup> in Colorectal Cancer Cells.
|
29527286 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor and adjacent healthy tissues were obtained from 100 patients diagnosed with CRC. miR-466 expression was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). mRNA and protein levels of cyclin D1, apoptosis regulator BAX (BAX), and matrix metalloproteinase-2 (MMP-2) were analyzed by qRT-PCR and Western blot, respectively, in SW-620 CRC cells transfected with miR-466 mimics or negative control miRNA.
|
29338680 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, CHRDL2 promoted CRC cell proliferation in vitro and in vivo, perhaps through up-regulation of Cyclin D1 and down-regulation of P21.
|
28009989 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that compared with GG homozygote genetic model, AA, AG, AA + AG genetic models of the CCND1 G870A polymorphism were significantly associated with overall CRC risk (AA homozygote genetic model: OR = 1.28, 95% CI = 1.10-1.49; AG heterozygote genetic model: OR = 1.15, 95% CI = 1.06-1.25; AA homozygote + AG heterozygote genetic model: OR = 1.19, 95% CI = 1.07-1.33).
|
29049220 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, the NONHSAT062994 expression status was negatively correlated with the Akt downstream targets c-Myc and Cyclin D1 in clinical CRC samples.
|
28978149 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DEGs may function in CRC by interacting with other genes in the PPI network of the top 50 nodes, for example, DEP domain‑containing MTOR‑interacting protein (DEPTOR)‑CCND1, AURKA‑breast carcinoma amplified sequence‑1 (BCAS1), CCND1‑BCAS1, CCND1‑neural precursor cell expressed developmentally downregulated 9 (NEDD9) and CCND1‑mitogen‑activated protein kinase kinase 2 (MAP2K2).
|
28000901 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study was designated to clarify whether common single nucleotide polymorphisms (SNPs) of the transcription factor 7- like 2 (TCF7L2) and cyclin D1 (CCND1) genes are associated with colorectal cancer risk in Mexican patients.
|
27755946 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclin-D1 and WEE1 were both downregulated in CRLM and CRC.
|
27492458 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues.
|
27191497 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings support the concept that the cell cycle regulation may play a role in colorectal cancer initiation and development and CCND1 A870G genotyping maybe a feasible technology for colorectal cancer early detection.
|
25809706 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggested PCNA, CCND1, NAT1 and NAT2 for use as biomarkers to enable early diagnosis and monitoring of CRC.
|
26239303 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The quantitative level of the β-catenin protein was significantly decreased in the CRC cell lysates, hence the expression level of c-Myc and cyclin D1 was significantly decreased following 2.5mM CaLa treatment.
|
26316447 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, to better understand the role of CCND1 and CDH1 in the pathophysiology of CRC, the expression pattern was evaluated in analogous tumor and adjacent normal tissues from 23 CRC patients by Western blot analysis.
|
25146682 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no significantly reduced risk of CRC by CHRT or ERT use, however a reduced risk of T-stage 1-2 tumours was seen among CHRT users (HR: 0.24; 95% CI: 0.09-0.77).Analysis stratified by tumour location revealed a reduced overall risk of rectal, but not colon, cancer among CHRT and ERT users, including T stage 1-2, lymph node negative, distant metastasis-free, cyclin D1 - and p53 negative tumours.In unadjusted analysis, OC use was significantly associated with a reduced overall risk of CRC (HR: 0.56; 95% CI: 0.44-0.71), but this significance was not retained in adjusted analysis (HR: 1.05: 95% CI: 0.80-1.37).
|
24885829 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results showed VEGF (71.4%), SOX9 (68.8%), MYC (62.3%), CCND1 (59.7%), TP53 (59.4%), MMP9 (53.3%), and BIRC5 (50.6%) as significantly overexpressed genes in CRC tissues.
|
24240588 |
2013 |